Using Multiple Drugs in Combination Helps Patients with Advanced AIDS. Ann Intern Med. 2001;135:S19. doi: 10.7326/0003-4819-135-1-200107030-00008
Download citation file:
Published: Ann Intern Med. 2001;135(1):S19.
Since 1996, combination therapies with antiretroviral drugs have been shown to increase length of life in many people with AIDS. (Drugs that suppress HIV, the virus that causes AIDS, are called antiretroviral drugs.) Combination therapy usually consists of taking three or four drugs of different types at the same time. Each of these drugs works in a different way against HIV. Combination therapy for AIDS is commonly called highly active antiretroviral therapy, or HAART. Currently, patients with newly diagnosed AIDS routinely receive HAART. Although we know that HAART can extend life for many of these patients, we do not know whether or how much HAART helps patients with severe or advanced, late-stage AIDS.
To find out whether HAART lengthens life and decreases medical complications in patients with advanced AIDS.
The study included 528 patients with advanced AIDS. All patients had severe anemia (low red blood cell counts) that required blood cell transfusions. Most were men (79%). One third of the patients were not taking any antiretroviral therapy when they entered the study, one quarter were already taking HAART, and the remainder were taking some antiretroviral therapies that are less intensive than HAART.
The researchers recruited and followed patients from 1995 to 1999. During routine quarterly visits, the researchers asked patients whether and when their doctors had started them on HAART. The researchers also reviewed medical records and pathology reports to find out whether any patients died or experienced infections or other medical complications related to AIDS.
Doctors more often prescribed HAART in the later years of the study than in the earlier years. For example, only 1% of the study patients had been given HAART as of January 1996, whereas 79% had been given it as of January 1999. During follow-up, 289 (55%) of the 528 patients died. Patients who took HAART lived longer and had fewer AIDS-related medical complications than patients who did not take HAART.
The researchers had limited ability to determine exactly whether the patients took HAART as prescribed. Also, many factors may contribute to better outcomes in patients with AIDS, and some of these factors may be related to whether patients took HAART. Although the investigators took into account many of these factors, sorting out whether the improved outcomes are due to HAART or other factors is very difficult.
Highly active antiretroviral therapy appears to lengthen life and decrease complications related to AIDS, even in patients with advanced AIDS.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Infectious Disease, HIV.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only